Engineered Outer Membrane Vesicles enhance solid tumor CAR-T cell therapy (PRJCA045259)

We developed a bacterial OMV-based immunosuppression reversal and optimized antigen decoration platform for CAR-T therapy (BROAD-CAR), in which OMVs were modified to express a high-affinity anti-PD-L1 antibody and load plasmids encoding the target antigen for CARs. By blocking the PD-1/PD-L1 signaling pathway, this tumour-targeting platform enhanced the anti-tumour activity of CAR-T cells both in vitro and in vivo, and boosted CAR-T cell expansion by ameliorating the tumour microenvironment.